Home / Business and Economy / Profit vs. Cash: Two Stocks Diverge Dramatically
Profit vs. Cash: Two Stocks Diverge Dramatically
9 Oct
Summary
- Kwality Pharma waits nearly seven months to collect payments.
- Maxgrow India's auditor raises serious concerns about its records.
- One stock shows profit growth but collection issues; the other flags audit risks.
Two companies, Kwality Pharmaceuticals and Maxgrow India, have captured investor attention with substantial stock gains, yet they present vastly different financial pictures. Kwality Pharma, incorporated in 1983 in Punjab, has seen its stock surge 296% in a year. While its net profit has doubled and margins widened, the company faces a critical issue: debtor days have ballooned to 203 days as of June 2026, indicating long payment collection cycles.
Maxgrow India, a metal trader, experienced an even more dramatic 852% stock increase. It reported rising profits for five consecutive quarters, with trailing twelve-month sales reaching Rs 26,261 crore. However, its financial health is clouded by a qualified audit report for the December 2025 quarter, citing missing statutory records and interest-free loans. The company also shows unusual zero interest, depreciation, and tax lines.
While Kwality Pharma's performance is tempered by its receivables, Maxgrow India's potential is overshadowed by significant audit concerns and a lack of public float. Investors are advised to monitor Kwality's debtor days and cash flow, and for Maxgrow, the focus is on audit compliance and promoter stake reduction. Both companies' September quarter results are keenly awaited.
